France · Source-listed medicine information
France / CIS 63740918
SMOFKABIVEN, émulsion pour perfusion
solution et solution et émulsion pour perfusion · intraveineuse
Source data retrieved: 2026-09-17. Clinical review is not yet available.
Product identity
At a glance
- Authorisation holder
- FRESENIUS KABI FRANCE
- Authorisation status
- Autorisation active
- Market status
- Commercialisée
- Country
- France
- Source reference
- CIS 63740918
Reported market status does not confirm current pharmacy stock.
From the official composition record
Ingredients & strength
Source entries are shown individually. An active substance (SA) and its reference moiety (FT) may describe the same ingredient; do not add their strengths together.
| Ingredient | Strength / reference | Source role |
|---|---|---|
| ALANINEcompartiment 1 : solution d'acides aminés | 14 g1000 ml | SAGroup 1 |
| LYSINE (ACÉTATE DE)compartiment 1 : solution d'acides aminés | 9,3 g1000 ml | SAGroup 7 |
| HISTIDINEcompartiment 1 : solution d'acides aminés | 3 g1000 ml | SAGroup 4 |
| ISOLEUCINEcompartiment 1 : solution d'acides aminés | 5 g1000 ml | SAGroup 5 |
| LEUCINEcompartiment 1 : solution d'acides aminés | 7,4 g1000 ml | SAGroup 6 |
| LYSINEcompartiment 1 : solution d'acides aminés | 6,6 g1000 ml | FTGroup 7 |
| PHÉNYLALANINEcompartiment 1 : solution d'acides aminés | 5,1 g1000 ml | SAGroup 9 |
| SÉRINEcompartiment 1 : solution d'acides aminés | 6,5 g1000 ml | SAGroup 11 |
| THRÉONINEcompartiment 1 : solution d'acides aminés | 4,4 g1000 ml | SAGroup 13 |
| TRYPTOPHANE Lcompartiment 1 : solution d'acides aminés | 2 g1000 ml | SAGroup 14 |
| VALINEcompartiment 1 : solution d'acides aminés | 6,2 g1000 ml | SAGroup 16 |
| GLYCINEcompartiment 1 : solution d'acides aminés | 11 g1000 ml | SAGroup 3 |
| ARGININEcompartiment 1 : solution d'acides aminés | 12 g1000 ml | SAGroup 2 |
| TAURINEcompartiment 1 : solution d'acides aminés | 1 g1000 ml | SAGroup 12 |
| MÉTHIONINEcompartiment 1 : solution d'acides aminés | 4,3 g1000 ml | SAGroup 8 |
| PROLINEcompartiment 1 : solution d'acides aminés | 11,2 g1000 ml | SAGroup 10 |
| TYROSINEcompartiment 1 : solution d'acides aminés | 0,4 g1000 ml | SAGroup 15 |
| GLUCOSE ANHYDREcompartiment 2 : solution de glucose | 420 g1000 ml | FTGroup 23 |
| GLUCOSE MONOHYDRATÉcompartiment 2 : solution de glucose | 462 g1000 ml | SAGroup 23 |
| HUILE DE SOJA RAFFINÉEcompartiment 3 : émulsion lipidique | 60 g1000 ml | SAGroup 25 |
| TRIGLYCÉRIDES À CHAÎNE MOYENNEcompartiment 3 : émulsion lipidique | 60 g1000 ml | SAGroup 26 |
| HUILE D'OLIVE RAFFINÉEcompartiment 3 : émulsion lipidique | 50 g1000 ml | SAGroup 27 |
| HUILE DE POISSON RICHE EN ACIDES OMÉGA-3 compartiment 3 : émulsion lipidique | 30 g1000 ml | SAGroup 28 |
Pack references
Presentations (5)
CIP13 3400926835750
Présentation active · Déclaration de commercialisationCIP13 3400939283814
Présentation active · Déclaration de commercialisationCIP13 3400939284064
Présentation active · Déclaration de commercialisationCIP13 3400939284293
Présentation active · Déclaration de commercialisationCIP13 3400939284415
Présentation active · Déclaration de commercialisationFrom the French medicines authority
Official documents
The official product entry provides access to the patient leaflet and professional product information when available. Documents are in French and availability varies by medicine.
Open the official product entryBDPM · CIS 63740918 · Opens in a new tabCheck the medicine name, strength and form against your pack. The authority’s current documents may be newer than the catalogue snapshot shown here.
Where this information comes from
Sources & dates
Base de données publique des médicaments (BDPM), France. Retrieval dates record when we obtained the source files; they are not clinical review dates or a guarantee of current stock.
| Source file | Retrieved | Source file modified |
|---|---|---|
| fr_products.txt | Not supplied | |
| fr_composition.txt | Not supplied | |
| fr_packs.txt | Not supplied |
Directory source checks cover the factual catalogue record.Molindra clinical guidance has not yet been reviewed or published for this medicine.
Our sources and review process →